All posts by: Michael Zand

About Michael Zand

ASH17: BioMarin’s gene therapy promises one-time treatment of hemophilia – BioPharma Dive

Continue reading

2017-12-09 NEWS

ASH17: BioMarin’s gene therapy promises one-time treatment of hemophilia
BioPharma Dive
An experimental gene therapy from BioMarin Pharmaceuticals Inc. dramatically reduced bleeding episodes in patients with hemophilia A, boosting levels of the blood clotting protein Factor VIII to near-normal or normal levels in 11 out of 13 patients

Continue reading

2017-12-09 NEWS

New Gene Therapy May Be Cure for ‘Bubble Boy’ Disease
U.S. News & World Report
SATURDAY, Dec. 9, 2017 (HealthDay News) — Babies born with the immune-system ravaging “bubble boy” disease have had to spend their too-often-short lives in germ-free isolation, lest something as simple as a common cold virus fell them with a fatal

and more »

Continue reading

2017-12-09 NEWS

EurekAlert (press release)

St. Jude gene therapy improves immunity in babies with ‘bubble boy’ disease
EurekAlert (press release)
Early evidence suggests that gene therapy developed at St. Jude Children’s Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. Preliminary results from the

and more »

Continue reading

2017-12-09 NEWS

EurekAlert (press release)

St. Jude gene therapy improves immunity in babies with ‘bubble boy’ disease
EurekAlert (press release)
Early evidence suggests that gene therapy developed at St. Jude Children’s Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. Preliminary results from the

and more »